A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels.

abstract：:Stroke remains the leading cause of neurological disability and the third leading cause of death worldwide, consuming a large share of total healthcare expenditures. In this review, we discuss the cost effectiveness of stroke prevention for various risk factor-modification programmes and pharmacological interventions ...

journal_title：PharmacoEconomics

authors： Alexandrov AV,Smurawska LT,Bartle W,Oh P

更新日期：1997-05-01 00:00:00

abstract：INTRODUCTION:Mixture modelling is increasingly being considered where a potential cure leads to a long life. Traditional methods use relative survival models for frail populations or cure models that have improper survival functions with theoretical infinite lifespans. Additionally, much of the work uses population dat...

journal_title：PharmacoEconomics

authors： Grant TS,Burns D,Kiff C,Lee D

更新日期：2020-04-01 00:00:00

abstract：OBJECTIVE:To estimate savings in the cost of caring for patients with Alzheimer's disease (AD) during 6 months, 1 year and 2 years of treatment with rivastigmine. An intermediate objective was to estimate the relationship between disease progression and institutionalisation. DESIGN AND SETTING:We assessed the relation...

journal_title：PharmacoEconomics

authors： Hauber AB,Gnanasakthy A,Snyder EH,Bala MV,Richter A,Mauskopf JA

更新日期：2000-04-01 00:00:00

abstract：:Pharmacoeconomic data may be obtained within the context of randomised clinical trials (RCTs) and from effectiveness studies in the 'real world'. The differences between the 2 types of study design have implications for the types of data that can be obtained and the interpretation of the resulting findings. Because RC...

journal_title：PharmacoEconomics

authors： Revicki DA,Frank L

更新日期：1999-05-01 00:00:00

abstract：:Epidural analgesia and intravenous analgesia with opioids are two techniques for providing pain relief for women in labour. Labour pain is comparable to surgical pain in its severity, and epidural analgesia provides better relief from this pain than intravenous analgesia; a meta-analysis quantified this improvement to...

journal_title：PharmacoEconomics

authors： Huang C,Macario A

更新日期：2002-01-01 00:00:00

abstract：:Most countries have healthcare resource constraints and it is easy to identify new health technologies as an area in need of resource management, particularly given that new health technologies usually increase rather than save costs. Resource constraints are even more noticeable in Asia than in other regions, with a ...

journal_title：PharmacoEconomics

authors： Yang BM

更新日期：2009-01-01 00:00:00

abstract：BACKGROUND:Cost-effectiveness analyses worldwide assume that the price of any single drug increases with inflation. New guidance from the Pharmaceutical Management Agency in New Zealand suggests that, when it is known that a generic drug will be available in the near future, a best estimate of the lower price of the ge...

journal_title：PharmacoEconomics

authors： Hoyle M

更新日期：2008-01-01 00:00:00

abstract：BACKGROUND:Of 1 346 700 total deaths each year in the US, an estimated 440 100 are smoking related, making it the leading preventable cause of premature death in the US. Despite the health and economic benefits of smoking cessation being well documented, reimbursement coverage for smoking cessation therapies is general...

journal_title：PharmacoEconomics

authors： Howard P,Knight C,Boler A,Baker C

更新日期：2008-01-01 00:00:00

abstract：:Direct administration of a drug into a vein guarantees bioavailability, i.e. the total amount of drug is fully available to the bloodstream for transport to all areas of the body. What is not ensured is the safety, need and 'value for money' of this route. Few workers would disagree that there is increased morbidity...

journal_title：PharmacoEconomics

authors： Parker SE,Davey PG

更新日期：1992-02-01 00:00:00

abstract：:Appropriate discounting rules in economic evaluations have received considerable attention in the literature and in national guidelines for economic evaluations. Rightfully so, as discounting can be quite influential on the outcomes of economic evaluations. The most prominent controversies regarding discounting involv...

journal_title：PharmacoEconomics

authors： Attema AE,Brouwer WBF,Claxton K

更新日期：2018-07-01 00:00:00

abstract：:Although decision making about what drugs to include in an institutional formulary appears to lend itself readily to quantitative techniques such as decision analysis and cost-benefit analysis, a review of the literature reveals that very little has been published in this area. Several of the published decision analy...

journal_title：PharmacoEconomics

authors： Schechter CB

更新日期：1993-06-01 00:00:00

abstract：:Whereas individual cost-effectiveness analyses of new agents for acute leukaemia should be performed in target populations, any meaningful pharmacoeconomic evaluation of treatment options for this condition should include the many types of costs and outcomes in unselected, representative groups of patients. Both direc...

journal_title：PharmacoEconomics

authors： Jønsson V,Hansen MM,Ljungman P,Kaasa S

更新日期：1999-02-01 00:00:00

abstract：:Vaccination is an underutilised, low cost and effective method of preventing illness. Cost-effectiveness analysis discloses a beneficial role of influenza vaccination in preventing illness especially in patients over 65 years of age and in high risk patients. In one large study, when 150 million doses of influenza v...

journal_title：PharmacoEconomics

authors： Perez-Tirse J,Gross PA

更新日期：1992-09-01 00:00:00

abstract：OBJECTIVE:The study objective was to evaluate and compare quality-of-life (QOL) parameters between patients with type 2 (non-insulin-dependent) diabetes mellitus who changed therapy from an oral hypoglycaemic agent (OHA) to insulin and those who remained on an OHA. DESIGN:The World Health Organization Quality of Life ...

journal_title：PharmacoEconomics

authors： Pibernik-Okanović M,Szabo S,Metelko Z

更新日期：1998-08-01 00:00:00

abstract：:An increasing number of ACE inhibitors have become available in recent years. Because these agents are all similar, careful scrutiny is required in order to determine specific advantages of particular agents when making formulary decisions. Differences between agents with regard to structure and tissue specificity hav...

journal_title：PharmacoEconomics

authors： Gerbrandt KR,Yedinak KC

更新日期：1996-12-01 00:00:00

abstract：:The National Institute for Health and Care Excellence (NICE) is only one of several organisations internationally that uses economic evaluation as part of decision making regarding funding and pricing of new medical technologies. However, it can be argued that NICE has developed a more prominent international profile ...

journal_title：PharmacoEconomics

authors： Sculpher M,Palmer S

更新日期：2020-03-01 00:00:00

abstract：:Discrete choice experiments (DCEs) are regularly used in health economics to elicit preferences for healthcare products and programmes. There is growing recognition that DCEs can provide more than information on preferences and, in particular, they have the potential to contribute more directly to outcome measurement ...

journal_title：PharmacoEconomics

authors： Lancsar E,Louviere J

更新日期：2008-01-01 00:00:00

abstract：:Answering the demanding questions asked of pharmacotherapy in the 21st century will require more reliance on the disciplines of pharmacoepidemiology and pharmacoeconomics. Pharmacoepidemiology can help assess patterns and appropriateness of drug utilisation, provide explanations for poor compliance, quantify the frequ...

journal_title：PharmacoEconomics

authors： Avorn J

更新日期：2004-01-01 00:00:00

abstract：:The lack of a uniform costing methodology is often considered a weakness of economic evaluations that hinders the interpretation and comparison of studies. Standardisation is therefore an important topic within the methodology of economic evaluations and in national guidelines that formulate the formal requirements fo...

journal_title：PharmacoEconomics

authors： Oostenbrink JB,Koopmanschap MA,Rutten FF

更新日期：2002-01-01 00:00:00

abstract：:Uncertainty in the decision-making process for reimbursement of health technologies could be reduced if additional information were available. Although methods to evaluate the monetary value of the uncertainty have been previously described, an economic evaluation of alternative methods to acquire additional informati...

journal_title：PharmacoEconomics

authors： Shavit O,Leshno M,Goldberger A,Shmueli A,Hoffman A

更新日期：2007-01-01 00:00:00

abstract：:Recent studies have shown that ACE inhibitors reduce morbidity and mortality after myocardial infarction (MI). While these trials have obvious clinical implications, the widespread introduction of a new treatment for a condition as common as MI also has clear cost implications. The results of the post-MI studies with ...

journal_title：PharmacoEconomics

authors： Hummel S,Piercy J,Wright R,Davie A,Bagust A,McMurray J

更新日期：1997-08-01 00:00:00

abstract：:The objective of this study was to demonstrate the cost effectiveness of long term maintenance treatment with citalopram versus standard therapy (defined as short term antidepressant treatment) in patients with major depression in Germany. We chose doxepin, amitriptyline and trimipramine as standard therapy because th...

journal_title：PharmacoEconomics

authors： Nuijten MJ,Hardens M,Souêtre E

更新日期：1995-08-01 00:00:00

abstract：:A variety of problems are associated with the operation, quality, costs, and benefits of therapeutic substitution programmes. Adequate communication of procedures, events, and failures are essential features of a safe therapeutic substitution policy. However, case reports of suboptimal therapy and differences in pha...

journal_title：PharmacoEconomics

authors： Levy RA

更新日期：1992-01-01 00:00:00

abstract：:Health economic modelling studies are of interest to many parties with different responsibilities and diverging interests. Therefore, it is obvious that recognising the relevance of statistical uncertainty and dealing with it appropriately are required to obtain unbiased results from health economic modelling studies,...

journal_title：PharmacoEconomics

authors： Nuijten MJ

更新日期：2004-01-01 00:00:00

abstract：:Over the last decade, there has been a proliferation in the number of economic evaluations of pharmaceuticals to meet the growing demand for information about the economic benefits of healthcare technologies. The majority of these studies have been commissioned by pharmaceutical companies for the purposes of drawing a...

journal_title：PharmacoEconomics

authors： Pang F

更新日期：2002-01-01 00:00:00

abstract：:The purpose of this study was to estimate the direct and indirect costs of alcoholism in the Federal Republic of Germany. Direct costs comprised treatment costs, while indirect costs consisted mainly of costs incurred as a result of work time lost, as well as costs related to premature retirement and premature mortali...

journal_title：PharmacoEconomics

authors： Brecht JG,Poldrugo F,Schädlich PK

更新日期：1996-11-01 00:00:00

abstract：:The pharmaceutical industry's core business is the innovation, development and marketing of new drugs. Pharmacogenetic (PG) testing and technology has the potential to increase a drug's value in many ways. A critical issue for the industry is whether products in development should be teamed with genetic tests that cou...

journal_title：PharmacoEconomics

authors： Vernon JA,Johnson SJ,Hughen WK,Trujillo A

更新日期：2006-01-01 00:00:00

abstract：BACKGROUND:During the 1990s, a number of new cytotoxic agents with clinically relevant activity in non-small-cell lung cancer (NSCLC), and with a more favourable therapeutic index than drugs already in use, became available. Given the high prices of these new drugs and the large number of patients affected, it is impor...

journal_title：PharmacoEconomics

authors： Neymark N,Lianes P,Smit EF,van Meerbeeck JP

更新日期：2005-01-01 00:00:00

abstract：:Several randomised comparative trials have shown that granulocyte colony-stimulating factor (G-CSF) reduces the duration of neutropenia, hospitalisation and intravenous antibacterial use in patients with cancer who are receiving high-dosage antineoplastic therapy. However, one area that has received less attention is ...

journal_title：PharmacoEconomics

authors： Dranitsaris G,Altmayer C,Quirt I

更新日期：1997-06-01 00:00:00

abstract：:Multiple sclerosis (MS) is a disease of the CNS, typically striking adults during the primary productive time of their life. The symptoms of MS can restrict the individual's physical activity and income-earning ability, resulting in a major financial burden on the patient, family, health system and society. This syste...

journal_title：PharmacoEconomics

authors： Naci H,Fleurence R,Birt J,Duhig A

更新日期：2010-01-01 00:00:00